Lupus Erythematosus
39
5
6
18
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.1%
2 terminated out of 39 trials
90.0%
+3.5% vs benchmark
5%
2 trials in Phase 3/4
11%
2 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (39)
Identification of Modifiable Sleep-related Factors in Patients With Systemic Lupus Erythematosus.
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
Cutaneous Lupus Registry
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
Psycho-social Consequences of Systemic Lupus Erythematosus
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
A Pilot Study to Explore the Role of Gut Flora in Lupus
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
A Study of Imvotamab in Severe Systemic Lupus Erythematosus
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
Trial of Belimumab in Early Lupus